Ultragenyx Pharmaceuticals Announces Presentation Of Data From A Single Patient Treated With Recombinant Human Beta-Glucuronidase At 10th Annual World Lysosomal Disease Network Symposium

NOVATO, Calif., Feb. 12, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced data presentations from a single patient treated with recombinant human beta-glucuronidase (rhGUS, UX003), an investigational therapy for the treatment of mucopolysaccharidosis 7 (MPS 7, Sly syndrome).

Help employers find you! Check out all the jobs and post your resume.